Regarding the endocrine treatment of PCa, other drugs were developed or are under study, such as anti-androgens [201,202], anti-AR [203,204,205], AR modulators [206,207] and degraders [208,209], glucocorticoid [210] and progesterone [211] receptor modulators, gonadotropin-releasing hormone agonists/antagonists [212], and steroid 17α-monooxygenase enzyme inhibitors [213,214]. The gene discussed is AR; the disease is posterior cortical atrophy.